Sangeeta Goswami, M.D., Ph.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
In the News
Allison Institute announces appointment of inaugural members
Physician-scientist driven to improve treatment options for kidney and bladder cancer patients
MD Anderson announces 2021 class of Andrew Sabin Family Fellows
Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer
Researchers identify immune-suppressing target in glioblastoma
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Baylor College of Medicine, Houston, TX, USA, PhD, Immunology |
| 2001 | Gauhati Medical College, Assam, IND, MD, Medicine |
Postgraduate Training
| 2013-2016 | Clinical Fellowship, Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2011-2013 | Clinical Residency, Internal Medicine, The University of Pittsburgh Medical Center, Pittsburgh, PA |
Board Certifications
| 2016 | American Board of Internal Medicine-Medical Oncology |
| 2015 | American Board of Internal Medicine-Internal Medicine |
Experience & Service
Other Appointments/Responsibilities
Postdoctoral Research Fellow, The University of Texas MD Anderson Cancer Center - Thoracic Head and Neck Medical Oncology, Houston, TX, 2009 - 2011
Research Associate, Institute of Genomics and Integrative Biology - Immunogenetics Lab, New Delhi, 2002 - 2003
Junior Resident Doctor, Sacred Home Hospital and Research Center, Ulubari, 2001 - 2002
Honors & Awards
| 2019 | Tang Fellowship in Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center |
| 2016 | Waun Ki Hong Award for Achievement in Basic Science Research |
| 2016 | American Society of Clinical Oncology (ASCO) Merit Award |
| 2007 | Outstanding Presentation-Basic Research, Department of Medicine Research Symposium, Baylor College of Medicine |
| 2006 | Best Poster Presentation, Department of Immunology, Baylor College of Medicine |
| 2005 | Best Research Proposal in Clinical Immunology, Baylor College Medicine |
| 2001 | Certification of Honor, Gauhati Medical College, India |
| 1996 | National Technical Scholarship, India |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
- Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. PMID: 34326169.
- Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci 1489(1):30-47, 2021. e-Pub 2020. PMID: 33184911.
- Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2020. PMID: 33187886.
- Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol 11:621591, 2021. e-Pub 2021. PMID: 33747934.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
- Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 12(548), 2020. PMID: 32554706.
- Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2019. PMID: 31873309.
- Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-3818, 2018. e-Pub 2018. PMID: 29905573.
- Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology 5(11):e1234570, 2016. e-Pub 2016. PMID: 27999749.
- Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241, 2014. e-Pub 2014. PMID: 25348003.
- Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 2013. e-Pub 2012. PMID: 23204236.
- Brooke V, Goswami S, Mohanty A, Kasi PM. Aortic dissection and renal failure in a patient with severe hypothyroidism. Case Rep Med 2012:842562, 2012. e-Pub 2012. PMID: 22829842.
- Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Song LZ, Redding D, Singh B, Sur S, Woodruff P, Dong C, Corry DB, Kheradmand F. Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat Immunol 10(5):496-503, 2009. e-Pub 2009. PMID: 19329997.
- Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB, Kheradmand F. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13(5):567-9, 2007. e-Pub 2007. PMID: 17450149.
- Zhao L, Leung JK, Yamamoto H, Goswami S, Kheradmand F, Vu TH. Identification of P311 as a potential gene regulating alveolar generation. Am J Respir Cell Mol Biol 35(1):48-54, 2006. e-Pub 2006. PMID: 16484684.
- Sharma M, Batra J, Mabalirajan U, Goswami S, Ganguly D, Lahkar B, Bhatia NK, Kumar A, Ghosh B. Suggestive evidence of association of C-159T functional polymorphism of the CD14 gene with atopic asthma in northern and northwestern Indian populations. Immunogenetics 56(7):544-7, 2004. e-Pub 2004. PMID: 15378299.
Invited Articles
- Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. PMID: 33811120.
- Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med 24(2):123-124, 2018. PMID: 29414936.
- Goswami S, Sharma P. Genetic biomarker for cancer immunotherapy. Science 357(6349):357(6349):358, 2017. PMID: 28751597.
- Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. Prostate 77(2):123-144, 2017. e-Pub 2016. PMID: 27679977.
- Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J 22(2):117-20, 2016. PMID: 27111907.
Abstracts
- Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang Z, Natarajan S, Xiong L, Guan B, Singh S, Saci A, Allison JP, Galsky MD, Sharma P.. Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer. Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting, 2021.
- Andreev-Drakhlin A, Shah AY, Adriazola AC, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Siefker-Radtke AO, Goswami S, Xiao L, Venkatesan AM, Campbell MT. Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting, 2021.
- Msaouel P, Gao J, Yuan Y, Siefker-Radtke AO, Jonasch E, Goswami S, Amado J. Zurita, Matthew T Campbell, Amishi Yogesh Shah, Paul G. Corn, Claudia Ramos, Xiaohong Yan, Curtis Chin, Hirak Der-Torossian, Nizar M. Tannir.. Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies. Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting, 2021.
- Siddiqui B, Gheeya JS, Goswamy R, Subudhi SK, Gao J, Shah AY, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Siefker-Radtke AO, Sharma P, Tannir N. Immune Checkpoint Therapy (ICT) re-Challenge after immune-related adverse events (irAEs) in genitourinary cancers: safety and efficacy. European Society for Medical Oncology (ESMO), Virtual Congress Meeting, 2020.
- Goswami S, Zhang X, Hao Z, Allison JP, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade therapy. American Society of Clinical Oncology (ASCO) Annual Meeting, 2016.
- Goswami S, Chen J, Zhao H, Zhang X, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade therapy. American Association of Clinical Research (AACR) Annual Meeting, 2016.
- Goswami S, Shi L, Sharma P. Ezh2 affects T cell differentiation. Immuno-Oncology Young Investigator Forum, 2015.
- Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou V, Wistuba II. Goswami S, Cortiz MA, Welsh J, Kurie JM, Heymach J. Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers. Annual ASCO (American Society of Clinical Oncology), 2014.
- Gibbons DL, Chen L, Goswami S, Cortez MA, Ahn YH, Byers LA, Win L, Diao L, Wang J, Roybal J, Ungewiss C, Antonia SJ, Mediaville-Varela M, Suraokar MB, Welsh J, Chen L, Wistuba II, Heymach J, Kurie JM, Qin FXF. Regulation of tumor cell PD-L1 expression by microRNA-200 and control of lung cancer metastasis. American Society of Clinical Oncology (ASCO) Annual Meeting, 2014.
- Goswami S, Ahn YH, Lin W, Mediavila-Varela M, Zhang X, Baruch E, Dwyer DW, Ungewiss C, Patel MP, Antonia S, Qin XF, Kurie JM. miR-200 suppression in tumor cells promotes metastasis by trigging intra-tumoral CD8+ T cell anergy. IDIBELL Cancer Conference on Metastasis and Angiogenesis, 2011.
- Goswami S, Lin W, Dwyer D, Qin XF, Kurie JM. Role of Inflammatory Cells in Lung Cancer Metastasis. Keystone Symposium, 2010.
- Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Sur S, Woodruff C, Dong C, Corry DB, Kheradmand F. Divergent Roles of Airway Epithelial MMP7 and Retinoic Acid in Experimental Asthma. The Journal of Immunology 182(1):Supplement, 2009.
- Goswami S, Barranco W, Greenlee KJ, Seryshev AB, Corry DB, Kheradmand F. Role of matrix-metalloprotease-7 in a model of experimental asthma. FASEB Journal, 2008.
- Goswami S, Barranco W, Lee SL, Corry DB, Kheradmand F. An autoimmune basis in the disease pathogenesis of COPD/Emphysema. The Journal of Immunology, 2007.
- Goswami S, Barranco W, Lee SL, Grudo A, Corry DB, Kheradmand F. An autoimmune basis in the disease pathogenesis of COPD/Emphysema. National Student Research Forum (NSRF), 2007.
- Lee SL, Goswami S, Grumelli S, Corry DB, Kheradmand F. Elastin derived peptide mediate autoimmune basis for smoking-induced emphysema in human. American Association of Immunologists (AAI), 2006.
Book Chapters
- Goswami S, Allison JP, Sharma P. Novel and Other Cancer Topics of Interest: Immuno-Oncology. In: The MD Anderson Manual of Medical Oncology: Third Edition. Third Edition. The McGraw-Hill Companies, Inc, 995-1002, 2016.
- Sharma P, Subudhi SK, Peggs K, Goswami S, Gao JJ, Quezada S, Allison JP. Chapter 13: Cancer Immunotherapy. In: Cancer Medicine 9th Edition. 9th Edition. Hong WK, Bast R, Hait WN Wiley, 2015.
- Massarelli E, Goswami S, Piha-Paul S. Section 1: Targets by Organ Site: Head and Neck Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer, 2014.
- Sharma A, Campbell M, Goswami S, Sharma P. Tumor Immunotherapy. In: Clinical Immunology: Principles and Practice. 5th Edition.
Grant & Contract Support
| Title: | Epigenetic Modulation with EZH2 Inhibition Can Overcome Resistance to Immune Checkpoint Therapy |
| Funding Source: | Emerson Collective Research Foundation |
| Role: | Principal Investigator |
| Title: | Epigenetic Immunomodulation in Immunocheckpoint Therapy Responses |
| Funding Source: | Khalifa Physician Scientist Award |
| Role: | Principal Investigator |
| Title: | Improving Anti-Tumor Responses to Immunotherapy Using the Combination Biomarker ARID1A and CXCL13 |
| Funding Source: | Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation |
| Role: | Co-Principal Investigator |
| Title: | A Pilot Study Evaluating the Clinical, Immunological, and Epigenetic Impact of EZH2 Inhibition in Overcoming Resistance to Immune Checkpoint Therapy in Genitourinary Malignancies |
| Funding Source: | Paul Calabresi Clinical Oncology Research Career Development Award |
| Role: | Recipient |
| Title: | A Study to Investigate the Role of Epigenetic Reprogramming in Improving Responses to Immune Checkpoint Therapy in Metastatic Renal Cell Carcinoma |
| Funding Source: | Cancer Research Institute |
| Role: | Principal Investigator |
| Title: | A Study to Investigate the Role of Epigenetic Reprogramming in Improving Responses to Immune Checkpoint Therapy in Metastatic Bladder Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Andrew Sabin Family Foundation |
| Role: | Principal Investigator |